SlideShare a Scribd company logo
Respiratory Emergencies
Asthma
• Asthma is a chronic respiratory disease characterized by periods of
variable and recurring symptoms, airflow obstruction, and bronchial
hyperresponsiveness that manifests clinically as attacks of impaired
breathing
• Asthma is an inflammatory disease; repetitive episodes of acute
superimposed on chronic airway inflammation are responsible for
alterations in airway function and result in irreversible structural
airway changes
• Asthma is thus a complex interaction of the immune system, the
environment, and genetic predispositions, which combine to alter
airway structure and function
European Respiratory Society/American Thoracic Society Definitions
of Severe and Uncontrolled Asthma
• Severe asthma for patients 6 years old and older is defined as:
Asthma which requires treatment with guidelines suggested
medications for Global Initiative for Asthma steps 4 to 5 asthma (high-
dose ICS and LABA or leukotriene modifier/ theophylline) for the
previous year or systemic corticosteroids for ≥50% of the previous
year to preventing it from becoming “uncontrolled” or which remains
“uncontrolled” despite this therapy
Uncontrolled asthma is defined as one of the following:
• Poor symptom control (ACQ consistently >1.5, ACT <20 (or “not well controlled” by
NAEPP/Global Initiative for Asthma guidelines)
• Frequent severe exacerbations: Two or more bursts of systemic corticosteroids (>3
days each) in previous year
• Serious exacerbations: At least one hospitalization, ICU stay, or mechanical
ventilation in the previous year
• Airflow limitation: After appropriate bronchodilator, withhold FEV1<80% predicted
(in the face of reduced FEV1 as less than the lower limit of normal)/FVC defined
• Controlled asthma that worsens on tapering of these high doses of ICS or systemic
corticosteroids (or additional biologics)
Treatment
COPD
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)
collaborators have updated their defnition of COPD as “a preventable and
treatable disease characterized by persistent airflow limitation that is
usually progressive and associated with an enhanced chronic inflamatory
response in the airways and the lungs to noxious particles or gas.”
• The definition specifically avoids mention of chronic bronchitis and
emphysema, two entities that have been traditionally included in the
definition of COPD
• the GOLD collaborators focus on airflow limitation as the principle feature
of the disease. Airflow limitation is a direct result of a combination of
parenchymal destruction and small airways disease. Both processes are a
consequence of chronic inflammatory changes and present clinically in
varying degrees amongst patients with COPD
• Progressive inflammation in COPD leads to airway limitation and obstruction.
However, not all patients who smoke or have exposure to noxious stimuli
develop COPD, raising the possibility that other contributory factors such as
genetics and environmental factors
• In COPD, evidence of airway inflammation is found from the trachea down to
the smallest peripheral airways. In the larger, more proximal airways, an
increase in both the number and size of mucous-secreting goblet cells can
result in the formation of mucous plugs, which further contributes to airflow
obstruction.
• Damage to the endothelium impairs the mucociliary response that clears
bacteria and mucous. Airway resistance and flow limitation are mainly due to
damage to the distal, smaller airways where the diameter is 2 mm or less.
• In cigarette smokers, the parenchymal damage will typically present in a
centriacinar pattern, especially in the early stages of the disease. Emphysema
is no longer routinely used in the definition of COPD, because it is a pathologic
and anatomically defined condition.
• Chronic bronchitis on the other hand is a clinical condition defined by the
presence of chronic productive cough for 3 months in each of 2 successive
years, where other causes of chronic cough have been excluded. Most patients
with COPD will have mixed features of both conditions.
• There is compelling evidence that protease/anti-protease imbalance plays a role
in the modification of the inflammatory cascade and resultant parenchymal
destruction seen in COPD. Protease-mediated destruction of connective tissues,
including elastin results in lung parenchymal damage and resultant emphysema.
• Anti-proteases protect against connective tissue destruction and are an integral
component in the pathogenesis of patients with congenital α1-antitrypsin
deficiency.
• Congenital α1-antitrypsin deficiency accounts for a small percentage of COPD
patients and is recognized by the lack of the anti-protease enzyme that inhibits
the protease enzyme, neutrophil elastase. The deficiency of this anti-protease
results in uninhibited protease action, parenchymal destruction, and severe
panacinar emphysema.
Proposed Indications for Mechanical Ventilation
• Respiratory arrest Worsening level of consciousness despite maximal
therapy
• Cardiovascular instability (shock, heart failure)
• NIPPV failure or exclusion criteria
• Severe dyspnea with use of accessory muscles and paradoxical abdominal
motion
• Severe tachypnea
• Life-threatening hypoxia
• Severe acidosis and hypercapnia
• Other complications (metabolic abnormalities, sepsis, pneumonia,
pulmonary embolism [PE], barotraumas, massive pleural effusion)
Pneumonia
• Pneumonia involves symptoms and signs of lower respiratory tract
infection (breathlessness, productive cough, and fever) usually
associated with CXR abnormalities. Pneumocystis pneumonia may
occur with minimal or no CXR changes. Consider pneumonia in
patients with septicaemia or acute confusional states.
• Pneumonia commonly results from microaspiration of upper
respiratory pathogens into the sterile lower respiratory tract. If the
challenge of invading organisms overwhelms host defenses, microbial
proliferation leads to inflammation, an immune response, and clinical
pneumonia.
• In patients admitted in the ICU the most common aetiologies were S. pneumoniae
(62%), atypical pathogens (14%) and polymicrobial aetiologies (11%). The most
frequent polymicrobial pattern was S. pneumoniae and viral infection, particularly
influenza virus .
• The microbial pattern of the severe CAP has changed over the years, with the decrease
of atypical pathogens, especially Legionella and the increase of viral pneumonia
• A large number of micro-organisms other than S. pneumoniae must be considered,
especially Pseudomonas aeruginosa, and CA—MRSA. The risk factors for Pseudomonas
pneumonia include
o ◆ Recent hospitalization.
◆ Frequent (>4 courses per year) or recent administration of antibiotics (last 3 months).
◆ Severe disease (FEV1 < 30%) and oral steroid use (>10 mg of prednisolone daily in the last 2
weeks).
• Accordingly, the risk factors for community-acquired methicillin-resistant
Staphylococcus aureus (CA-MRSA), an emerging problem, are participating in contact
sport, living in crowded or unsanitary conditions, intravenous drug abuse
• CA-MRSA is the most common pathogen isolated in community-acquired skin and soft
tissue infections. It causes severe, rapidly progressing pneumonia with sepsis, often in
children or healthy young adults with influenza
American Thoracic Society/Infectious Disease Society of America
Definitions of Hospital Acquired, Ventilator-Associated, and Health
Care–Associated Pneumonia
• Hospital-acquired pneumonia (HAP)—occurs ≥48 hr after admission and
does not appear to be incubating at the time of admission
• Ventilator-associated pneumonia (VAP)—occurs >48–72 hr after
endotracheal intubation
• Health care–associated pneumonia (HCAP)—occurs in a non hospitalized
patient with extensive health care contact defined by one or more of the
following exposures
• IV therapy, wound care, or IV chemotherapy within the prior 30 days Residence in a
nursing home or other long-term care facility
• Hospitalization in an acute care hospital for 2 or more days within the past 90 days
• Received hemodialysis within the prior 30 day.
Organ colonization time-evolution during ICU stay.
*At 48 hours 80% of ETT are colonized, but heavy colonization occurs at
60–96 hours.
Criteria for ICU admission.
One of the major or three
or more of the minor
criteria would indicate ICU
admission
Pneumothorax
• Pneumothorax is defined as the presence of air in the intrapleural space
and can range from a benign to a life-threatening process.
• A spontaneous pneumothorax occurs in the absence of any external
precipitating factor, traumatic or iatrogenic.
• Primary spontaneous pneumothorax occurs in individuals without clinically
apparent lung disease.
• Secondary spontaneous pneumothorax arises in the context of an
underlying pulmonary disease process.
• Tension pneumothorax is a life-threatening complication resulting from
pressure in the pleural cavity causing hemodynamic compromise.
Causes of Secondary Spontaneous Pneumothorax
AIRWAY DISEASE
• Chronic obstructive pulmonary disease
• Asthma
• Cystic fibrosis
INFECTIONS
• Necrotizing bacterial pneumonia,
• lung abscess
• Pneumocystis jiroveci
• pneumonia
• Tuberculosis
INTERSTITIAL LUNG DISEASE
• Sarcoidosis
• Idiopathic pulmonary fibrosis
• Lymphangiomyomatosis
• Tuberous sclerosis
• Pneumoconioses
NEOPLASMS
• Primary lung cancers
• Pulmonary or pleural metastases
The classic radiographic appearance is that of a thin, visceral pleural line lying parallel to the chest wall,
separated by a radiolucent band devoid of lung markings. The average width of this band can be used to
estimate the size of the pneumothorax, such as with the Rhea method
British Thoracic Society
guidelines define size
based on measurement
of the intrapleural
distance at the level of
the hilum: small, less than
1 cm; moderate, 1 to 2
cm; and large, more than
2 cm.
The American College
of Chest Physicians
measures from the apex
to the cupola(chest wall
apex)—small is less than
3 cm, and large is more
than 3 cm.
Deep venous thrombosis
• The triad of venous injury, slow blood flow, and hypercoagulability are the
cardinal inciting mechanisms for VTE, and most clinical decision rules for VTE
incorporate these factors.
Diagnosis
• Diagnosis of DVT and PE starts with an estimation of the pretest
probability (PTP).
• the LEFt score:
• 1 point in case of left (L) leg suspicion,
• 1 point for edema (E), and
• 1 point if the suspicion occurred during the first trimester (Ft) of pregnancy,
• with a score of 0 or 1 tantamount to a low PTP
• The PTP dictates the pathway for diagnostic testing
A three-point
ultrasound includes
the common femoral,
femoral, and
popliteal veins. A
whole-leg ultrasound
includes a three-
point ultrasound and
the peroneal and
tibial calf veins.
• Upper extremity DVT can cause PE, and all patients with DVT above the elbow
require definitive treatment.: About half of all upper extremity DVTs are
associated with an indwelling catheter, and peripherally inserted central
catheters (PICCs) carry the highest risk.
• Acute PE from an axillary vein Isolated upper occurs in about 9% of patients
with arm DVT, although the PE tends to be less severe from upper extremity
DVT
• only venous ultrasound has been adequately validated as a method to
diagnose and exclude upper extremity DVT
PULMONARY EMBOLISM
• A PE results when a clot that formed hours, days, or sometimes weeks
earlier in the deep veins dislodges, travels through the venous system, and
traverses the right ventricle into the pulmonary vasculature.
• The mortality of diagnosed and treated pulmonary embolism is 7%. Many
more people die from undiagnosed PE. Venous thromboembolism
develops in patients already suffering from sepsis, cancer, or COPD or in
patients recovering from stroke, MI, surgery, and joint replacement.
• Pulmonary embolic disease can result in a variety of symptoms often
misdiagnosed as asthma, anxiety, pneumonia and ACS
• The right ventricle normally pumps through a pulmonary vascular tree with a
low resistance to fluid flow, and young persons without cardiopulmonary
disease (eg, congestive heart failure, chronic obstructive lung disease,
advanced sarcoidosis, pulmonary fibrosis, scleroderma, primary pulmonary
hypertension) can tolerate at least 30% obstruction from a clot, with minimal
symptoms or signs.
• Pulmonary infarction, in contrast, can produce severe pleuritic pain Although
a segmental pulmonary artery constitutes only about 1/16 of the entire
pulmonary vascular circuit, a clot lodged deeply in a segmental artery can
obstruct blood flow to a sufficient degree to cause tissue necrosis.
Pulmonary Embolism Rule-Out Criteria (PERC
Rule)
Low pretest probability for PE by the treating emergency clinician’s
unstructured estimate, plus all the following must be true:
• Age < 50 yr
• Pulse rate < 100 beats/min
• Oxygen saturation < 94%
• No hemoptysis
• No unilateral leg swelling
• No recent major surgery or trauma
• No prior pulmonary embolism or deep venous thrombosis
• No hormone use
• Chest radiography seldom provides specific information, but is useful to
suggest alternative diagnoses, such as pneumonia, congestive heart failure, or
pneumothorax.
• If symptoms have been present for 3 days or more, a pulmonary infarction may
be visible on chest x-ray as an apex central, pleural-based, wedge-shaped area
of infiltrate, producing the so-called Hampton’s hump finding. Unilateral lung
oligemia (Westermark’s sign) is a rare radiographic manifestation of a large PE.
• When PE causes electrocardiographic changes, this is usually a result of acute
or subacute pulmonary hypertension. The most common effects of pulmonary
hypertension on the ECG are rapid heart rate, symmetric T-wave inversion in
the anterior leads (V1–V4), the McGinn White S1Q3T3 pattern, and incomplete
or complete right bundle branch block
• In the ED, inability to identify a cause of chest symptoms or specific signs may
be an important cue to evaluate the patient for PE
PLEURAL INFLAMMATION AND
EFFUSION
• Pleural effusion implies the presence of an abnormal collection of fluid in
the pleural space.
• A pleural effusion associated with bacterial pneumonia or lung abscess is
termed a parapneumonic effusion. The term pleural empyema (or
pyothorax) implies the presence of actual pus in the pleural space. Fluid
that is anatomically confined and not freely flowing within the pleural
space is termed a loculated effusion.
• Loculated effusions occur when there are adhesions between the visceral
and parietal pleurae
Respiratory emergencies Emergency medicine
Respiratory emergencies Emergency medicine
Respiratory emergencies Emergency medicine
Respiratory emergencies Emergency medicine
Respiratory emergencies Emergency medicine
Respiratory emergencies Emergency medicine
Respiratory emergencies Emergency medicine
Respiratory emergencies Emergency medicine
Respiratory emergencies Emergency medicine
Respiratory emergencies Emergency medicine

More Related Content

What's hot

Bronchiectasis
BronchiectasisBronchiectasis
Bronchiectasis
Amr Eldakroury
 
Bronchial asthma and it's management
Bronchial asthma and it's managementBronchial asthma and it's management
Bronchial asthma and it's management
RakhiYadav53
 
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease  Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
YMC Medicine
 
Pneumonia
PneumoniaPneumonia
Asthma and COPD exacerbation - Emergency
Asthma and COPD exacerbation - Emergency  Asthma and COPD exacerbation - Emergency
Asthma and COPD exacerbation - Emergency
Areej Abu Hanieh
 
COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
COPD (CHRONIC  OBSTRUCTIVE  PULMONARY  DISEASE)COPD (CHRONIC  OBSTRUCTIVE  PULMONARY  DISEASE)
COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
kalyan kumar
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumoniaSaba Khan
 
Bronchitis ppt
Bronchitis pptBronchitis ppt
Bronchitis ppt
Dr Mahavrat Patel
 
Empyema
EmpyemaEmpyema
Empyema
GAMANDEEP
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)
CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)
CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)
Suraj Dhara
 
Pneumonia
PneumoniaPneumonia
Pneumonia
Eko Priyanto
 
Asthma medical, nursing managements
Asthma medical, nursing managementsAsthma medical, nursing managements
Asthma medical, nursing managementsReynel Dan
 
COPD
COPDCOPD
Emphysema
EmphysemaEmphysema
Bronchitis
BronchitisBronchitis
Pleurisy
PleurisyPleurisy
Pleurisy
Shahrukh Ahamd
 
Upper respiratory infections
Upper respiratory infectionsUpper respiratory infections
Upper respiratory infections
JOFREY MTEWELE
 
Respiratory Disorders
Respiratory DisordersRespiratory Disorders
Respiratory Disorders
Nio Noveno
 
Emphysema ppt
Emphysema pptEmphysema ppt
Emphysema ppt
VemuJhansi
 

What's hot (20)

Bronchiectasis
BronchiectasisBronchiectasis
Bronchiectasis
 
Bronchial asthma and it's management
Bronchial asthma and it's managementBronchial asthma and it's management
Bronchial asthma and it's management
 
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease  Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Asthma and COPD exacerbation - Emergency
Asthma and COPD exacerbation - Emergency  Asthma and COPD exacerbation - Emergency
Asthma and COPD exacerbation - Emergency
 
COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
COPD (CHRONIC  OBSTRUCTIVE  PULMONARY  DISEASE)COPD (CHRONIC  OBSTRUCTIVE  PULMONARY  DISEASE)
COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumonia
 
Bronchitis ppt
Bronchitis pptBronchitis ppt
Bronchitis ppt
 
Empyema
EmpyemaEmpyema
Empyema
 
COPD
COPDCOPD
COPD
 
CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)
CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)
CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Asthma medical, nursing managements
Asthma medical, nursing managementsAsthma medical, nursing managements
Asthma medical, nursing managements
 
COPD
COPDCOPD
COPD
 
Emphysema
EmphysemaEmphysema
Emphysema
 
Bronchitis
BronchitisBronchitis
Bronchitis
 
Pleurisy
PleurisyPleurisy
Pleurisy
 
Upper respiratory infections
Upper respiratory infectionsUpper respiratory infections
Upper respiratory infections
 
Respiratory Disorders
Respiratory DisordersRespiratory Disorders
Respiratory Disorders
 
Emphysema ppt
Emphysema pptEmphysema ppt
Emphysema ppt
 

Similar to Respiratory emergencies Emergency medicine

Respiratory disease and anesthesia
Respiratory disease and anesthesiaRespiratory disease and anesthesia
Respiratory disease and anesthesia
Sunakshi Bhatia
 
Asthma.pptx
Asthma.pptxAsthma.pptx
Asthma.pptx
jiregna5
 
Copd lecture notes
Copd lecture notesCopd lecture notes
Copd lecture noteshomebwoi
 
COPD(Chronic Obstructive Pulmonary Disease)Ayurveda
COPD(Chronic Obstructive Pulmonary Disease)AyurvedaCOPD(Chronic Obstructive Pulmonary Disease)Ayurveda
COPD(Chronic Obstructive Pulmonary Disease)Ayurveda
RaghavendraPujari1
 
COPD for Hussamaldin Hassan Elsied Ahmed subspecialty students at SMSB
COPD for  Hussamaldin Hassan Elsied Ahmed subspecialty students at SMSBCOPD for  Hussamaldin Hassan Elsied Ahmed subspecialty students at SMSB
COPD for Hussamaldin Hassan Elsied Ahmed subspecialty students at SMSB
hossamahmed1110
 
COPD.pptx
COPD.pptxCOPD.pptx
DRUG INDUCED PULMONARY DISEASE.pptx
DRUG INDUCED PULMONARY DISEASE.pptxDRUG INDUCED PULMONARY DISEASE.pptx
DRUG INDUCED PULMONARY DISEASE.pptx
AvaniPatel718642
 
Bronchectasis
BronchectasisBronchectasis
Bronchectasis
THANUJA MATHEW
 
Ckd chief (2)
Ckd chief (2)Ckd chief (2)
Ckd chief (2)
Rajiv Lal
 
Refractory asthma
Refractory asthmaRefractory asthma
Refractory asthma
Saher Farghly
 
COPD-dr. Khalfan s khalfan, MD From B.M.C
COPD-dr. Khalfan s khalfan, MD From B.M.CCOPD-dr. Khalfan s khalfan, MD From B.M.C
COPD-dr. Khalfan s khalfan, MD From B.M.C
SwizzyKhalfa
 
01.copd
01.copd01.copd
01.copd
Dragon Yott
 
Copd phenotypes
Copd phenotypesCopd phenotypes
Copd phenotypes
Anusha Jahagirdar
 
Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)
Rahil Dalal
 
interstitial lung diseses and idiopathic pulmonary fibrosis
interstitial lung diseses and idiopathic pulmonary fibrosisinterstitial lung diseses and idiopathic pulmonary fibrosis
interstitial lung diseses and idiopathic pulmonary fibrosis
bannu medical college bannu KPK pakistan
 
L3 4 .copd
L3 4 .copdL3 4 .copd
L3 4 .copd
bilal natiq
 
Asthma
AsthmaAsthma
COPD
COPDCOPD
Asthma.pptx
Asthma.pptxAsthma.pptx
Asthma.pptx
AshwaniMaurya20
 

Similar to Respiratory emergencies Emergency medicine (20)

Respiratory disease and anesthesia
Respiratory disease and anesthesiaRespiratory disease and anesthesia
Respiratory disease and anesthesia
 
Asthma.pptx
Asthma.pptxAsthma.pptx
Asthma.pptx
 
Copd lecture notes
Copd lecture notesCopd lecture notes
Copd lecture notes
 
COPD(Chronic Obstructive Pulmonary Disease)Ayurveda
COPD(Chronic Obstructive Pulmonary Disease)AyurvedaCOPD(Chronic Obstructive Pulmonary Disease)Ayurveda
COPD(Chronic Obstructive Pulmonary Disease)Ayurveda
 
COPD for Hussamaldin Hassan Elsied Ahmed subspecialty students at SMSB
COPD for  Hussamaldin Hassan Elsied Ahmed subspecialty students at SMSBCOPD for  Hussamaldin Hassan Elsied Ahmed subspecialty students at SMSB
COPD for Hussamaldin Hassan Elsied Ahmed subspecialty students at SMSB
 
COPD.pptx
COPD.pptxCOPD.pptx
COPD.pptx
 
DRUG INDUCED PULMONARY DISEASE.pptx
DRUG INDUCED PULMONARY DISEASE.pptxDRUG INDUCED PULMONARY DISEASE.pptx
DRUG INDUCED PULMONARY DISEASE.pptx
 
Bronchectasis
BronchectasisBronchectasis
Bronchectasis
 
Ckd chief (2)
Ckd chief (2)Ckd chief (2)
Ckd chief (2)
 
Refractory asthma
Refractory asthmaRefractory asthma
Refractory asthma
 
COPD-dr. Khalfan s khalfan, MD From B.M.C
COPD-dr. Khalfan s khalfan, MD From B.M.CCOPD-dr. Khalfan s khalfan, MD From B.M.C
COPD-dr. Khalfan s khalfan, MD From B.M.C
 
01.copd
01.copd01.copd
01.copd
 
Copd phenotypes
Copd phenotypesCopd phenotypes
Copd phenotypes
 
Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)Chronic obstructive pulmonary disease (copd)
Chronic obstructive pulmonary disease (copd)
 
interstitial lung diseses and idiopathic pulmonary fibrosis
interstitial lung diseses and idiopathic pulmonary fibrosisinterstitial lung diseses and idiopathic pulmonary fibrosis
interstitial lung diseses and idiopathic pulmonary fibrosis
 
L3 4 .copd
L3 4 .copdL3 4 .copd
L3 4 .copd
 
Asthma
AsthmaAsthma
Asthma
 
COPD
COPDCOPD
COPD
 
Asthma.pptx
Asthma.pptxAsthma.pptx
Asthma.pptx
 
COPD ppt
COPD pptCOPD ppt
COPD ppt
 

Recently uploaded

ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Dr KHALID B.M
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 

Recently uploaded (20)

ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyayaCharaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
Charaka Samhita Sutra Sthana 9 Chapter khuddakachatuspadadhyaya
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 

Respiratory emergencies Emergency medicine

  • 2. Asthma • Asthma is a chronic respiratory disease characterized by periods of variable and recurring symptoms, airflow obstruction, and bronchial hyperresponsiveness that manifests clinically as attacks of impaired breathing • Asthma is an inflammatory disease; repetitive episodes of acute superimposed on chronic airway inflammation are responsible for alterations in airway function and result in irreversible structural airway changes • Asthma is thus a complex interaction of the immune system, the environment, and genetic predispositions, which combine to alter airway structure and function
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8. European Respiratory Society/American Thoracic Society Definitions of Severe and Uncontrolled Asthma • Severe asthma for patients 6 years old and older is defined as: Asthma which requires treatment with guidelines suggested medications for Global Initiative for Asthma steps 4 to 5 asthma (high- dose ICS and LABA or leukotriene modifier/ theophylline) for the previous year or systemic corticosteroids for ≥50% of the previous year to preventing it from becoming “uncontrolled” or which remains “uncontrolled” despite this therapy
  • 9.
  • 10. Uncontrolled asthma is defined as one of the following: • Poor symptom control (ACQ consistently >1.5, ACT <20 (or “not well controlled” by NAEPP/Global Initiative for Asthma guidelines) • Frequent severe exacerbations: Two or more bursts of systemic corticosteroids (>3 days each) in previous year • Serious exacerbations: At least one hospitalization, ICU stay, or mechanical ventilation in the previous year • Airflow limitation: After appropriate bronchodilator, withhold FEV1<80% predicted (in the face of reduced FEV1 as less than the lower limit of normal)/FVC defined • Controlled asthma that worsens on tapering of these high doses of ICS or systemic corticosteroids (or additional biologics)
  • 11.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20. COPD • Global Initiative for Chronic Obstructive Lung Disease (GOLD) collaborators have updated their defnition of COPD as “a preventable and treatable disease characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflamatory response in the airways and the lungs to noxious particles or gas.” • The definition specifically avoids mention of chronic bronchitis and emphysema, two entities that have been traditionally included in the definition of COPD • the GOLD collaborators focus on airflow limitation as the principle feature of the disease. Airflow limitation is a direct result of a combination of parenchymal destruction and small airways disease. Both processes are a consequence of chronic inflammatory changes and present clinically in varying degrees amongst patients with COPD
  • 21.
  • 22. • Progressive inflammation in COPD leads to airway limitation and obstruction. However, not all patients who smoke or have exposure to noxious stimuli develop COPD, raising the possibility that other contributory factors such as genetics and environmental factors • In COPD, evidence of airway inflammation is found from the trachea down to the smallest peripheral airways. In the larger, more proximal airways, an increase in both the number and size of mucous-secreting goblet cells can result in the formation of mucous plugs, which further contributes to airflow obstruction. • Damage to the endothelium impairs the mucociliary response that clears bacteria and mucous. Airway resistance and flow limitation are mainly due to damage to the distal, smaller airways where the diameter is 2 mm or less. • In cigarette smokers, the parenchymal damage will typically present in a centriacinar pattern, especially in the early stages of the disease. Emphysema is no longer routinely used in the definition of COPD, because it is a pathologic and anatomically defined condition.
  • 23. • Chronic bronchitis on the other hand is a clinical condition defined by the presence of chronic productive cough for 3 months in each of 2 successive years, where other causes of chronic cough have been excluded. Most patients with COPD will have mixed features of both conditions. • There is compelling evidence that protease/anti-protease imbalance plays a role in the modification of the inflammatory cascade and resultant parenchymal destruction seen in COPD. Protease-mediated destruction of connective tissues, including elastin results in lung parenchymal damage and resultant emphysema. • Anti-proteases protect against connective tissue destruction and are an integral component in the pathogenesis of patients with congenital α1-antitrypsin deficiency. • Congenital α1-antitrypsin deficiency accounts for a small percentage of COPD patients and is recognized by the lack of the anti-protease enzyme that inhibits the protease enzyme, neutrophil elastase. The deficiency of this anti-protease results in uninhibited protease action, parenchymal destruction, and severe panacinar emphysema.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33. Proposed Indications for Mechanical Ventilation • Respiratory arrest Worsening level of consciousness despite maximal therapy • Cardiovascular instability (shock, heart failure) • NIPPV failure or exclusion criteria • Severe dyspnea with use of accessory muscles and paradoxical abdominal motion • Severe tachypnea • Life-threatening hypoxia • Severe acidosis and hypercapnia • Other complications (metabolic abnormalities, sepsis, pneumonia, pulmonary embolism [PE], barotraumas, massive pleural effusion)
  • 34. Pneumonia • Pneumonia involves symptoms and signs of lower respiratory tract infection (breathlessness, productive cough, and fever) usually associated with CXR abnormalities. Pneumocystis pneumonia may occur with minimal or no CXR changes. Consider pneumonia in patients with septicaemia or acute confusional states. • Pneumonia commonly results from microaspiration of upper respiratory pathogens into the sterile lower respiratory tract. If the challenge of invading organisms overwhelms host defenses, microbial proliferation leads to inflammation, an immune response, and clinical pneumonia.
  • 35.
  • 36. • In patients admitted in the ICU the most common aetiologies were S. pneumoniae (62%), atypical pathogens (14%) and polymicrobial aetiologies (11%). The most frequent polymicrobial pattern was S. pneumoniae and viral infection, particularly influenza virus . • The microbial pattern of the severe CAP has changed over the years, with the decrease of atypical pathogens, especially Legionella and the increase of viral pneumonia • A large number of micro-organisms other than S. pneumoniae must be considered, especially Pseudomonas aeruginosa, and CA—MRSA. The risk factors for Pseudomonas pneumonia include o ◆ Recent hospitalization. ◆ Frequent (>4 courses per year) or recent administration of antibiotics (last 3 months). ◆ Severe disease (FEV1 < 30%) and oral steroid use (>10 mg of prednisolone daily in the last 2 weeks). • Accordingly, the risk factors for community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), an emerging problem, are participating in contact sport, living in crowded or unsanitary conditions, intravenous drug abuse • CA-MRSA is the most common pathogen isolated in community-acquired skin and soft tissue infections. It causes severe, rapidly progressing pneumonia with sepsis, often in children or healthy young adults with influenza
  • 37. American Thoracic Society/Infectious Disease Society of America Definitions of Hospital Acquired, Ventilator-Associated, and Health Care–Associated Pneumonia • Hospital-acquired pneumonia (HAP)—occurs ≥48 hr after admission and does not appear to be incubating at the time of admission • Ventilator-associated pneumonia (VAP)—occurs >48–72 hr after endotracheal intubation • Health care–associated pneumonia (HCAP)—occurs in a non hospitalized patient with extensive health care contact defined by one or more of the following exposures • IV therapy, wound care, or IV chemotherapy within the prior 30 days Residence in a nursing home or other long-term care facility • Hospitalization in an acute care hospital for 2 or more days within the past 90 days • Received hemodialysis within the prior 30 day.
  • 38. Organ colonization time-evolution during ICU stay. *At 48 hours 80% of ETT are colonized, but heavy colonization occurs at 60–96 hours.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44. Criteria for ICU admission. One of the major or three or more of the minor criteria would indicate ICU admission
  • 45.
  • 46.
  • 47.
  • 48.
  • 49. Pneumothorax • Pneumothorax is defined as the presence of air in the intrapleural space and can range from a benign to a life-threatening process. • A spontaneous pneumothorax occurs in the absence of any external precipitating factor, traumatic or iatrogenic. • Primary spontaneous pneumothorax occurs in individuals without clinically apparent lung disease. • Secondary spontaneous pneumothorax arises in the context of an underlying pulmonary disease process. • Tension pneumothorax is a life-threatening complication resulting from pressure in the pleural cavity causing hemodynamic compromise.
  • 50.
  • 51.
  • 52. Causes of Secondary Spontaneous Pneumothorax AIRWAY DISEASE • Chronic obstructive pulmonary disease • Asthma • Cystic fibrosis INFECTIONS • Necrotizing bacterial pneumonia, • lung abscess • Pneumocystis jiroveci • pneumonia • Tuberculosis INTERSTITIAL LUNG DISEASE • Sarcoidosis • Idiopathic pulmonary fibrosis • Lymphangiomyomatosis • Tuberous sclerosis • Pneumoconioses NEOPLASMS • Primary lung cancers • Pulmonary or pleural metastases
  • 53.
  • 54.
  • 55.
  • 56.
  • 57. The classic radiographic appearance is that of a thin, visceral pleural line lying parallel to the chest wall, separated by a radiolucent band devoid of lung markings. The average width of this band can be used to estimate the size of the pneumothorax, such as with the Rhea method
  • 58. British Thoracic Society guidelines define size based on measurement of the intrapleural distance at the level of the hilum: small, less than 1 cm; moderate, 1 to 2 cm; and large, more than 2 cm. The American College of Chest Physicians measures from the apex to the cupola(chest wall apex)—small is less than 3 cm, and large is more than 3 cm.
  • 59.
  • 60.
  • 62. • The triad of venous injury, slow blood flow, and hypercoagulability are the cardinal inciting mechanisms for VTE, and most clinical decision rules for VTE incorporate these factors.
  • 63.
  • 64.
  • 65. Diagnosis • Diagnosis of DVT and PE starts with an estimation of the pretest probability (PTP). • the LEFt score: • 1 point in case of left (L) leg suspicion, • 1 point for edema (E), and • 1 point if the suspicion occurred during the first trimester (Ft) of pregnancy, • with a score of 0 or 1 tantamount to a low PTP • The PTP dictates the pathway for diagnostic testing
  • 66.
  • 67. A three-point ultrasound includes the common femoral, femoral, and popliteal veins. A whole-leg ultrasound includes a three- point ultrasound and the peroneal and tibial calf veins.
  • 68.
  • 69.
  • 70. • Upper extremity DVT can cause PE, and all patients with DVT above the elbow require definitive treatment.: About half of all upper extremity DVTs are associated with an indwelling catheter, and peripherally inserted central catheters (PICCs) carry the highest risk. • Acute PE from an axillary vein Isolated upper occurs in about 9% of patients with arm DVT, although the PE tends to be less severe from upper extremity DVT • only venous ultrasound has been adequately validated as a method to diagnose and exclude upper extremity DVT
  • 71. PULMONARY EMBOLISM • A PE results when a clot that formed hours, days, or sometimes weeks earlier in the deep veins dislodges, travels through the venous system, and traverses the right ventricle into the pulmonary vasculature. • The mortality of diagnosed and treated pulmonary embolism is 7%. Many more people die from undiagnosed PE. Venous thromboembolism develops in patients already suffering from sepsis, cancer, or COPD or in patients recovering from stroke, MI, surgery, and joint replacement. • Pulmonary embolic disease can result in a variety of symptoms often misdiagnosed as asthma, anxiety, pneumonia and ACS
  • 72.
  • 73.
  • 74. • The right ventricle normally pumps through a pulmonary vascular tree with a low resistance to fluid flow, and young persons without cardiopulmonary disease (eg, congestive heart failure, chronic obstructive lung disease, advanced sarcoidosis, pulmonary fibrosis, scleroderma, primary pulmonary hypertension) can tolerate at least 30% obstruction from a clot, with minimal symptoms or signs. • Pulmonary infarction, in contrast, can produce severe pleuritic pain Although a segmental pulmonary artery constitutes only about 1/16 of the entire pulmonary vascular circuit, a clot lodged deeply in a segmental artery can obstruct blood flow to a sufficient degree to cause tissue necrosis.
  • 75.
  • 76.
  • 77.
  • 78. Pulmonary Embolism Rule-Out Criteria (PERC Rule) Low pretest probability for PE by the treating emergency clinician’s unstructured estimate, plus all the following must be true: • Age < 50 yr • Pulse rate < 100 beats/min • Oxygen saturation < 94% • No hemoptysis • No unilateral leg swelling • No recent major surgery or trauma • No prior pulmonary embolism or deep venous thrombosis • No hormone use
  • 79.
  • 80. • Chest radiography seldom provides specific information, but is useful to suggest alternative diagnoses, such as pneumonia, congestive heart failure, or pneumothorax. • If symptoms have been present for 3 days or more, a pulmonary infarction may be visible on chest x-ray as an apex central, pleural-based, wedge-shaped area of infiltrate, producing the so-called Hampton’s hump finding. Unilateral lung oligemia (Westermark’s sign) is a rare radiographic manifestation of a large PE. • When PE causes electrocardiographic changes, this is usually a result of acute or subacute pulmonary hypertension. The most common effects of pulmonary hypertension on the ECG are rapid heart rate, symmetric T-wave inversion in the anterior leads (V1–V4), the McGinn White S1Q3T3 pattern, and incomplete or complete right bundle branch block • In the ED, inability to identify a cause of chest symptoms or specific signs may be an important cue to evaluate the patient for PE
  • 81.
  • 82. PLEURAL INFLAMMATION AND EFFUSION • Pleural effusion implies the presence of an abnormal collection of fluid in the pleural space. • A pleural effusion associated with bacterial pneumonia or lung abscess is termed a parapneumonic effusion. The term pleural empyema (or pyothorax) implies the presence of actual pus in the pleural space. Fluid that is anatomically confined and not freely flowing within the pleural space is termed a loculated effusion. • Loculated effusions occur when there are adhesions between the visceral and parietal pleurae